Arcus Biosciences Inc
NYSE:RCUS

Watchlist Manager
Arcus Biosciences Inc Logo
Arcus Biosciences Inc
NYSE:RCUS
Watchlist
Price: 15.95 USD -2.92%
Market Cap: 1.5B USD
Have any thoughts about
Arcus Biosciences Inc?
Write Note

Arcus Biosciences Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Arcus Biosciences Inc
Cash & Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Arcus Biosciences Inc
NYSE:RCUS
Cash & Cash Equivalents
$201m
CAGR 3-Years
4%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash & Cash Equivalents
$7.3B
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
-1%
Gilead Sciences Inc
NASDAQ:GILD
Cash & Cash Equivalents
$5B
CAGR 3-Years
5%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Cash & Cash Equivalents
$9B
CAGR 3-Years
-9%
CAGR 5-Years
-5%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash & Cash Equivalents
$6.5B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash & Cash Equivalents
$2B
CAGR 3-Years
-16%
CAGR 5-Years
8%
CAGR 10-Years
12%

See Also

What is Arcus Biosciences Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
201m USD

Based on the financial report for Sep 30, 2024, Arcus Biosciences Inc's Cash & Cash Equivalents amounts to 201m USD.

What is Arcus Biosciences Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
21%

Over the last year, the Cash & Cash Equivalents growth was 9%. The average annual Cash & Cash Equivalents growth rates for Arcus Biosciences Inc have been 4% over the past three years , 21% over the past five years .

Back to Top